{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:14:07Z","timestamp":1783498447273,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00415-026-13924-9","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:33:32Z","timestamp":1782887612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Number needed to treat and harm for lecanemab and donanemab in early Alzheimer disease"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-2063","authenticated-orcid":false,"given":"Marco","family":"Spallazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Zilioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Ruffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Pietro","family":"Imbimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"1","key":"13924_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"13924_CR2","unstructured":"US Food and Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee meeting: lecanemab briefing document. Published 2023. Accessed March 23, 2026. https:\/\/www.fda.gov\/media\/169264\/download"},{"key":"13924_CR3","unstructured":"US Food and Drug Administration. Leqembi (lecanemab-irmb) prescribing information. Published 2025. Accessed March 23, 2026. https:\/\/www.accessdata.fda.gov"},{"issue":"6","key":"13924_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM et al (2023) Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330(6):512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"13924_CR5","unstructured":"US Food and Drug Administration. Integrated review for donanemab (TRAILBLAZER-ALZ 2). Published 2024. Accessed March 23, 2026. https:\/\/www.accessdata.fda.gov"},{"key":"13924_CR6","unstructured":"US Food and Drug Administration. Donanemab prescribing information. Published 2025. Accessed March 23, 2026. https:\/\/www.accessdata.fda.gov"},{"key":"13924_CR7","unstructured":"European Medicines Agency. Kisunla (donanemab) EPAR: public assessment report. Published 2024. Accessed March 23, 2026. https:\/\/www.ema.europa.eu"},{"key":"13924_CR8","doi-asserted-by":"publisher","unstructured":"Wang H, Serap Monkul Nery E, Ardayfio P, Khanna R, Otero Svaldi D, Gueorguieva I et al. (2025) Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimers Dement 21(4):e70062. https:\/\/doi.org\/10.1002\/alz.70062. Erratum in: Alzheimers Dement 21(8):e70576. 10.1002\/alz.70576","DOI":"10.1002\/alz.70062"},{"issue":"7","key":"13924_CR9","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0319-23.2024","volume":"11","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Kepp KP, Herrup K (2024) Lecanemab and Donanemab as therapies for Alzheimer\u2019s disease: An illustrated perspective on the data. eNeuro 11(7):ENEURO.0319-23.2024. https:\/\/doi.org\/10.1523\/ENEURO.0319-23.2024","journal-title":"eNeuro"},{"issue":"3","key":"13924_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200621","volume":"16","author":"A Atri","year":"2026","unstructured":"Atri A, Apostolova LG, Iwata A, Wessels AM, Atkins A, Lu M, Ye W, Ryan S, Doty EG (2026) Clinical meaningfulness of donanemab in early symptomatic Alzheimer disease: data from the randomized phase 3 TRAILBLAZER-ALZ 2 trial. Neurol Clin Pract 16(3):e200621. https:\/\/doi.org\/10.1212\/CPJ.0000000000200621","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"13924_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-026-09082-5","volume":"47","author":"M Spallazzi","year":"2026","unstructured":"Spallazzi M, Zilioli A, Capellari S (2026) Pooling Alzheimer\u2019s disease: when methodological rigor risks obscuring biological complexity. Neurol Sci 47(6):477. https:\/\/doi.org\/10.1007\/s10072-026-09082-5","journal-title":"Neurol Sci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13924-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13924-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13924-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:21:19Z","timestamp":1783495279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13924-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["13924"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13924-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS reports serving as a site investigator in clinical trials in Alzheimer\u2019s disease, including trials of anti-amyloid therapies. No other disclosures were reported. AZ and LR report no disclosures. BI reports being an employee at Chiesi Farmaceutici. He is listed among the inventors of a number of Chiesi Farmaceutici\u2019s patents of anti-Alzheimer drugs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable, as this study is based exclusively on previously published data and does not involve human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"436"}}